Reports
Sale
Neuroendocrine Tumours Treatment Market Size, Share, Growth: By Treatment: Targeted Therapy, Chemotherapy, Somatostatin Analogues (SSAs), Others; By Route of Administration: Oral, Parenteral; By Disease Indication: Gastrointestinal NET, Lung NET, Pancreatic NET, Others; Regional Analysis; Supplier Landscape; 2024-2032
Neuroendocrine Tumours Treatment Market Size
The neuroendocrine tumours treatment market was valued at USD 2.45 billion in 2023, driven by the rising incidence of neuroendocrine tumours and advancements in treatment modalities across the 8 major markets. The market is expected to grow at a CAGR of 8.23% during the forecast period of 2024-2032, with the values likely to reach USD 4.30 billion by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Neuroendocrine Tumours Treatment Market Outlook
- There is a rising incidence of neuroendocrine tumours globally. The improved diagnostic capabilities and awareness among healthcare providers have led to more frequent detection and diagnosis of NETs. This trend is expected to drive market growth as more patients seek treatment.
- The treatment landscape for neuroendocrine tumours has seen considerable advancements. Targeted therapies such as somatostatin analogs, peptide receptor radionuclide therapy (PRRT), and molecularly targeted agents have demonstrated efficacy in managing NETs. These treatments offer improved outcomes and quality of life for patients, thereby increasing their adoption and contributing to market growth.
- There is ongoing research focused on understanding the underlying biology of neuroendocrine tumours and developing novel therapeutic approaches. Continued innovation in R&D is expected to expand treatment options and further drive market growth.
Neuroendocrine Tumours Treatment Market Overview
Neuroendocrine tumours (NETs) are a diverse group of neoplasms that arise from cells of the neuroendocrine system. These cells are found throughout the body, particularly in organs such as the gastrointestinal tract, pancreas, and lungs. Neuroendocrine cells are specialized cells that have characteristics of both nerve cells (neurons) and hormone-producing cells (endocrine cells). They produce hormones and release them into the bloodstream in response to signals from the nervous system.
The market for neuroendocrine tumours treatment has been growing steadily due to rising incidence rates globally and improved diagnostic capabilities. NETs are considered rare, but their recognition and diagnosis have been increasing, leading to a growing patient pool seeking treatment. The treatment options for NETs include surgery, chemotherapy, targeted therapy (such as somatostatin analogs and mTOR inhibitors), peptide receptor radionuclide therapy (PRRT), and others. The treatment market is driven by the increasing incidence of NETs, growing awareness among healthcare providers and patients, advancements in personalized medicine approaches, and ongoing clinical trials evaluating new therapies and combinations and driving the market growth.
Neuroendocrine Tumours Treatment Market Growth Drivers
Increasing Incidence and Awareness
As awareness about neuroendocrine tumours increase among healthcare providers and the general population, the scope of early detection is higher. Early detection is critical because NETs are often slow-growing and may not cause symptoms until they reach an advanced stage. Improved early detection leads to earlier intervention and treatment, which can potentially improve patient outcomes and survival rates.
There has been a documented increase in the incidence of neuroendocrine tumours globally. This increase is partly due to improvements in diagnostic techniques and surveillance, which have led to better recognition and reporting of NETs cases. Cancer Australia reported that 1 in 55 people were at risk of being diagnosed with neuroendocrine tumours by the age of 85 (1 in 52 for males and 1 in 58 for females) in 2022. As the number of diagnosed cases rises, there is a corresponding increase in the demand for treatment options and thus augmenting the market growth.
Expanding Treatment Options is Expected to Propel Neuroendocrine Tumours Treatment Market Demand
The treatment landscape for NETs has expanded with the introduction of targeted therapies such as somatostatin analogues, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). These therapies offer more effective options compared to traditional chemotherapy, driving market growth as they become the standard of care in many regions.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Neuroendocrine Tumours Treatment Market Trends
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
| Key Trends | Impact |
| Advancements in Targeted Therapies | There has been significant progress in the development of targeted therapies for NETs, such as somatostatin analogs, mTOR inhibitors, and peptide receptor radionuclide therapy (PRRT). These therapies are designed to specifically target the molecular pathways involved in NETs, leading to improved treatment outcomes and reduced side effects compared to traditional chemotherapy. These advancements are expected to drive the market growth. |
| Clinical Trials and Research Initiatives | The ongoing clinical trials and research efforts are expanding the understanding of NETs biology and evaluating novel therapeutic approaches. Research initiatives focus on exploring new drug targets, combination therapies, and immunotherapy strategies, which have the potential to further improve patient outcomes and expand the treatment landscape. |
| Rise in Strategic Partnerships | The neuroendocrine tumours treatment market is influenced by strategic mergers and acquisitions activities among manufacturers, healthcare providers, and technology companies that are driving innovation and fostering market expansion. These collaborations are accelerating the development of advanced products and augmenting the market reach globally. |
| Integration of Biomarkers | Biomarkers play a crucial role in diagnosing NETs, predicting treatment response, and monitoring disease progression. The integration of novel biomarkers into clinical practice is enhancing diagnostic accuracy and guiding treatment decisions. Biomarker-driven approaches also support the development of targeted therapies and companion diagnostics. |
Neuroendocrine Tumours Treatment Market Segmentation
Market Breakup by Treatment
- Targeted Therapy
- Chemotherapy
- Somatostatin Analogues (SSAs)
- Other
Market Breakup by Route of Administration
- Oral
- Parenteral
Market Breakup by Disease Indication
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Neuroendocrine Tumours Treatment Market Share
Market Segmentation Based on Treatment is Anticipated to Witness Substantial Growth
By treatment, the market is segmented into targeted therapy, chemotherapy, somatostatin analogues (SSAs) and others. The somatostatin analogues (SSAs) segment is dominating the market as somatostatin analogues such as octreotide and lanreotide are effective in controlling symptoms associated with functional NETs, such as carcinoid syndrome. These drugs work by inhibiting the secretion of hormones such as serotonin, histamine, and others, which are responsible for increasing its market share.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Neuroendocrine Tumours Treatment Market Analysis by Region
Based on the region, the market covers the United States, EU-4 (Germany, France, Italy, Spain), the United Kingdom, Japan and India. The United States is dominating the market share due to increasing technological innovations, along with a relatively high incidence and prevalence of neuroendocrine tumours compared to other regions. Improved diagnostic capabilities, increased awareness among healthcare providers, and enhanced surveillance contribute to the detection of more NET cases. This high disease burden drives the demand for effective treatment options in the region.
EU-4 also holds a high neuroendocrine tumours treatment market value due to its well-established infrastructure, specialized medical centres, and skilled healthcare professionals. The availability of comprehensive oncology services, including state-of-the-art imaging technologies, advanced surgical techniques, and access to clinical trials, supports the diagnosis and treatment of NETs at various stages and thus driving the regional demand.
Additionally, Japan and India are expected to witness substantial market growth, fueled by the growing patient pool suffering from diseases and increasing collaboration and funding initiatives.
Leading Players in the Neuroendocrine Tumours Treatment Market
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding and investment analysis and other strategic initiatives by the leading players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer Inc. has been involved in the research and development of treatments for various medical conditions, including neuroendocrine tumors (NETs). Pfizer has a vast portfolio that includes medications for oncology.
Novartis AG
Novartis AG is a pharmaceutical company actively involved in the research and development of treatments for various medical conditions, including neuroendocrine tumors (NETs).
Ipsen Pharma SA
Ipsen Pharma SA is actively involved in the field of neuroendocrine tumors (NETs) treatment through its oncology portfolio. Ipsen has developed and marketed several medications specifically for NETs. One notable example is Somatuline (lanreotide), which is used for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and carcinoid syndrome.
Other key players in the market include Abbvie Inc., AVEO Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Hutchison MediPharma Limited, Tarveda Therapeutics, Progenics Pharmaceuticals, Inc., and Eli Lilly & Company among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Disease Indication |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Key Questions Answered in the Neuroendocrine Tumours Treatment Market Report
- What was the neuroendocrine tumours treatment market value in 2023?
- What is the neuroendocrine tumours treatment market forecast outlook for 2024-2032?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment?
- What is market segmentation based on the route of administration?
- What is market segmentation based on disease indication?
- What are the major factors aiding the neuroendocrine tumours treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major trends influencing the market?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How does the prevalence of neuroendocrine tumours affect the market landscape?
- How does the growing technological advancements in treatments impact the market size?
- Which disease indication area is expected to have a high market value in the coming years?
- Who are the key players involved in the neuroendocrine tumours treatment market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Neuroendocrine Tumours Treatment Market Overview: 8 Major Markets
3.1 Neuroendocrine Tumours Treatment Market Historical Value (2017-2023)
3.2 Neuroendocrine Tumours Treatment Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Neuroendocrine Tumours Treatment Market: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Neuroendocrine Tumours Treatment Market Epidemiology Scenario and Forecast – 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2017-2032)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Neuroendocrine Tumours Treatment Market Landscape: 8 Major Market*
8.1 Neuroendocrine Tumours Treatment Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.2 Neuroendocrine Tumours Treatment Market: Product Landscape
8.2.1 Analysis by Type of Treatment
8.2.2 Analysis by Route of Administration
8.2.3 Analysis by Disease Indication
9 Neuroendocrine Tumours Treatment Market Therapy Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Neuroendocrine Tumours Treatment: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Neuroendocrine Tumours Treatment Market Segmentation: 8 Major Market
12.1 Neuroendocrine Tumours Treatment Market by Treatment
12.1.1 Market Overview
12.1.2 Targeted Therapy
12.1.3 Chemotherapy
12.1.4 Somatostatin Analogues (SSAs)
12.1.5 Others
12.2 Neuroendocrine Tumours Treatment Market by Route of Administration
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Parenteral
12.3 Neuroendocrine Tumours Treatment Market by Disease Indication
12.3.1 Market Overview
12.3.2 Gastrointestinal NET
12.3.3 Lung NET
12.3.4 Pancreatic NET
12.3.5 Others
12.4 Neuroendocrine Tumours Treatment Market by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Neuroendocrine Tumours Treatment Market (2017-2032)
13.1 United States Neuroendocrine Tumours Treatment Market Historical Value (2017-2023)
13.2 United States Neuroendocrine Tumours Treatment Market Forecast Value (2024-2032)
13.3 United States Neuroendocrine Tumours Treatment Market by Treatment
13.3.1 Market Overview
13.3.2 Targeted Therapy
13.3.3 Chemotherapy
13.3.4 Somatostatin Analogues (SSAs)
13.3.5 Others
13.4 United States Neuroendocrine Tumours Treatment Market by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Parenteral
13.5 United States Neuroendocrine Tumours Treatment Market by Disease Indication
13.5.1 Market Overview
13.5.2 Gastrointestinal NET
13.5.3 Lung NET
13.5.4 Pancreatic NET
13.5.5 Others
14 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market (2017-2032)
14.1 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market Historical Value (2017-2023)
14.2 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market Forecast Value (2024-2032)
14.3 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market by Treatment
14.3.1 Market Overview
14.3.2 Targeted Therapy
14.3.3 Chemotherapy
14.3.4 Somatostatin Analogues (SSAs)
14.3.5 Others
14.4 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Parenteral
14.5 EU-4 and United Kingdom Neuroendocrine Tumours Treatment Market by Disease Indication
14.5.1 Market Overview
14.5.2 Gastrointestinal NET
14.5.3 Lung NET
14.5.4 Pancreatic NET
14.5.5 Others
15 Japan Neuroendocrine Tumours Treatment Market
15.1 Japan Neuroendocrine Tumours Treatment Market Historical Value (2017-2023)
15.2 Japan Neuroendocrine Tumours Treatment Market Forecast Value (2024-2032)
15.3 Japan Neuroendocrine Tumours Treatment Market by Treatment
15.3.1 Market Overview
15.3.2 Targeted Therapy
15.3.3 Chemotherapy
15.3.4 Somatostatin Analogues (SSAs)
15.3.5 Others
15.4 Japan Neuroendocrine Tumours Treatment Market by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Parenteral
15.5 Japan Neuroendocrine Tumours Treatment Market by Disease Indication
15.5.1 Market Overview
15.5.2 Gastrointestinal NET
15.5.3 Lung NET
15.5.4 Pancreatic NET
15.5.5 Others
16 India Neuroendocrine Tumours Treatment Market
16.1 India Neuroendocrine Tumours Treatment Market (2017-2032) Historical Value (2017-2023)
16.2 India Neuroendocrine Tumours Treatment Market (2017-2032) Forecast Value (2024-2032)
16.3 India Neuroendocrine Tumours Treatment Market by Treatment
16.3.1 Market Overview
16.3.2 Targeted Therapy
16.3.3 Chemotherapy
16.3.4 Somatostatin Analogues (SSAs)
16.3.5 Others
16.4 India Neuroendocrine Tumours Treatment Market by Route of Administration
16.4.1 Market Overview
16.4.2 Oral
16.4.3 Parenteral
16.5 India Neuroendocrine Tumours Treatment Market by Disease Indication
16.5.1 Market Overview
16.5.2 Gastrointestinal NET
16.5.3 Lung NET
16.5.4 Pancreatic NET
16.5.5 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share Analysis, By Region (Top 5 Companies)
23.2 Pfizer Inc.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Novartis AG
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Ipsen Pharma SA
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Abbvie Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 AVEO Pharmaceuticals, Inc.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 BoehringerIngelheim International GmbH
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Hutchison MediPharma Limited
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Tarveda Therapeutics
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Progenics Pharmaceuticals, Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Eli Lilly & Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
24 Neuroendocrine Tumours Treatment Market – Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER